A pet probiotic capable of improving the intestinal flora structure of dogs and its application

Through the novel Pediococcus acidilacticic strain DC-S001 isolated from healthy dogs, the problem of antibiotics destroying intestinal microorganisms was solved, significantly improved the intestinal microbial structure of dogs, increased the number of beneficial bacteria, reduced the growth of harmful bacteria, and achieved safety Efficient bacterial regulation.

CN118703407BActive Publication Date: 2024-11-15LITTLE PET (BEIJING) TECH CO LTD
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202411204762.3
Authority / Receiving Office
CN · China
Patent Type
Patents(China)
Current Assignee / Owner
Filing Date
2024-08-30
Publication Date
2024-11-15
Estimated Expiration
2044-08-30

AI Technical Summary

Technical Problem

Existing antibiotics can destroy intestinal microorganisms when treating gastrointestinal diseases, resulting in flora disorders, and their use is limited, and there is a lack of safe and effective methods to improve the intestinal microbial structure of dogs.

Method used

A novel strain of Pediococcus acidilacticici was isolated from the intestines of healthy dogs. The safety and effect were verified through safety evaluation and functional tests. It is used to improve the intestinal microbial structure of dogs and inhibit the growth of harmful bacteria. , increase the number of beneficial bacteria.

Benefits of technology

By increasing the proportion of Lactobacillus and Pseudomonas aeruginosa, the proportion of Bacteroidetes was reduced, the intestinal microbiota structure of the dog was significantly improved, the species abundance and diversity of the microbiota were reduced, and no virulence factor-related genes and antibiotics were found. sexual genes ensure safety.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN118703407B_ABST
    Figure CN118703407B_ABST
Patent Text Reader

Abstract

The present invention relates to a pet probiotic capable of improving the structure of canine intestinal flora and its application, belonging to the field of biotechnology. In order to overcome the deficiency of existing antibiotics in damaging intestinal microorganisms and thus causing disorder of intestinal flora, the present invention provides a pet probiotic capable of improving the structure of canine intestinal flora, and the strain is deposited in the China General Microbiological Culture Collection Center with a deposit number of CGMCC No. 27239. Safety evaluation proves that the lactic acid Pediococcus is safe and non-toxic and does not produce antibiotic resistance, and functional tests prove that the pet probiotic can increase the number of beneficial bacteria, inhibit the growth of harmful bacteria, and improve the structure of intestinal flora.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The invention relates to a pet probiotic capable of improving the intestinal flora structure of a dog and application thereof, belonging to the field of biotechnology. Background Art

[0002] The intestinal flora is considered to be an "organ". The composition of the intestinal flora is affected by various factors such as age, nutrition and environment. Some changes caused by these factors can have a beneficial effect on the host's intestinal health, while other changes can destroy the original microbial structure and lead to imbalance, thus causing gastrointestinal disorders and even systemic, metabolic or autoimmune diseases. The intestinal flora has been recognized as an important factor in various physiological processes of the host, including energy supply and demand, metabolism, immune response and neural development, improved interaction with other body cells, digestion, host metabolism, vitamin synthesis, bile acid conversion, maturation of gastrointestinal cells and defense against pathogens.

[0003] The structure of intestinal flora is closely related to the health of the body. When the balance of intestinal flora is disrupted, it often causes a decline in body function and causes a variety of diseases. For example, in dogs with chronic intestinal diseases, acute hemorrhagic diarrhea syndrome and intestinal cancer, changes in the flora structure or metabolites and a reduction in beneficial bacteria (such as Fusobacterium and Faecalibacterium) can be observed in dogs. The intestinal flora can also interact with the nervous system in a bidirectional manner through the gut-brain axis, causing neuroimmune inflammatory responses, intestinal mucosal and blood-brain barrier dysfunction, and causing nervous system diseases. Dysbiosis of intestinal flora can cause bile acid metabolism disorders. Bile acid (BA) plays an important role in lipid digestion. Bacteria in the intestine are responsible for BA uncoupling and dehydroxylation, so dysbiosis can impair the production of secondary BA. Chronic intestinal diseases also reduce the expression of apical sodium-dependent bile acid transporter (ASBT), which is essential for the reabsorption of coupled primary BA. Tryptophan is a precursor for the production of indole compounds, which can only be synthesized by bacteria and are involved in the expression of genes involved in maintaining intestinal homeostasis, reducing intestinal permeability, and increasing mucin production. Tryptophan is the only amino acid that is reduced in the serum of dogs with protein-losing enteropathy, a chronic intestinal disease.

[0004] The current purpose of antibiotics in the treatment of acute and chronic gastrointestinal diseases is to remove pathogenic bacteria. However, during treatment, antibiotics can also damage intestinal microorganisms, leading to intestinal flora disorders. Therefore, the appropriateness of antibiotic prescriptions should be evaluated based on specific circumstances, rather than being used as a standard treatment for gastrointestinal diseases. In recent years, the country's restrictions on the use of antibiotics have become increasingly stringent, and people have paid close attention to the nutrition of companion pets. Probiotic products that have a positive effect and great potential in animal health have attracted more and more attention. Major pet companies have also invested in this field, and the market prospects for functional pet food will be broader.

[0005] Probiotics are microorganisms that are beneficial to the body. The beneficial effects of probiotics are achieved by improving the composition of the host's intestinal microbiota. They can effectively improve the structure of the intestinal flora, inhibit the growth and reproduction of harmful bacteria, and promote the increase in the number of beneficial bacteria. Probiotics can work through a variety of mechanisms, such as secreting lipase, amylase, cellulase, protease, glucosidase and other enzymes. They are often used for digestive problems caused by insufficient secretion of endogenous digestive enzymes in young animals. Therefore, introducing beneficial bacterial species into the gastrointestinal tract is a reasonable choice to restore microbial balance and prevent diseases. Summary of the invention

[0006] In order to overcome the shortcomings of existing antibiotics that damage intestinal microorganisms and thus cause intestinal flora disorders, the present invention provides a pet probiotic that can improve the intestinal flora structure of dogs. Safety evaluation proves that the lactic acid Pediococcus is safe, non-toxic and does not produce antibiotic resistance. Functional tests prove that the pet probiotic can increase the number of beneficial bacteria, inhibit the growth of harmful bacteria, and improve the intestinal flora structure.

[0007] The present invention achieves the above technical effects through the following technical solutions:

[0008] A pet probiotic capable of improving the intestinal flora structure of dogs, which is isolated from the intestines of healthy dogs, and the strain is deposited in the China General Microbiological Culture Collection Center (address: No. 3, Yard No. 1, Beichen West Road, Chaoyang District, Beijing), with a deposit number of CGMCC No. 27239, and is classified as Pediococcus acidilactici Pediococcus acidilactici , strain number DC-S001.

[0009] The above-mentioned method for isolating and screening pet probiotics that can improve the intestinal flora structure of dogs is as follows: the small intestine of a healthy dog ​​is lavaged with sterile PBS buffer and the small intestinal lavage fluid of the dog is collected, the small intestinal lavage fluid of the dog is diluted in a 10-fold gradient, and evenly spread on a plate of MRS selective culture medium, anaerobically cultured at 37-40°C for 24-48 hours, and the milky white colonies are picked out.

[0010] The pet probiotics capable of improving the intestinal flora structure of dogs are characterized by Gram staining, microscopic observation of bacterial morphology, and classification and identification using 16S rRNA sequencing. The lactic acid Pediococcus is a Gram-positive bacterium with milky white colonies. 16S rRNA sequencing identifies that it is different from the existing lactic acid Pediococcus and is a new strain. Pediococcus acidilactici The homology is 88.76%.

[0011] As mentioned above, pet probiotics that can improve the intestinal flora structure of dogs, Pediococcus acidilactici ( Pediococcus acidilactici ), through whole genome sequencing, the genome sequence was analyzed and compared with the comprehensive database of virulence factors of pathogens (VFDB) and the comprehensive antibiotic resistance database (CARD) by BLAST, and no virulence factor-related genes and antibiotic resistance genes were found.

[0012] The present invention also claims to protect a use of the above-mentioned pet probiotics, that is, the use of the pet probiotics in improving the intestinal flora structure of dogs.

[0013] Example 2 of the present invention analyzed the Alpha diversity of the intestinal flora of dogs in the control group (Con), the competitive product group (BLD) and the experimental group (Probiotic). The results showed that the Saccharomyces boulardii probiotics and the pet probiotics of the present invention can reduce the species abundance and diversity of the intestinal flora of dogs. The PCOA method was used to analyze the Beta diversity of the intestinal flora of dogs. The results showed that the intestinal flora of the dogs in the control group (Con), the competitive product group (BLD) and the experimental group (Probiotic) had clustered into completely different classification clusters ( Figure 4 ). Therefore, the intestinal flora of dogs in the control group (Con), the competitive product group (BLD) and the experimental group (Probiotic) have their own characteristics. In order to further analyze the changes in the community of canine intestinal flora, the present invention compared and analyzed the changes in the species composition of the intestinal flora of the competitive product group and the control group after probiotic intervention at the phylum classification level and the genus classification level ( Figure 5 ). The results of the analysis at the phylum level showed that the ratio (F / B) of Firmicutes to Bacteroidota in the probiotic intervention group decreased, the average proportion of Fusobacteriota and Campylobacterota decreased, and the average proportion of Proteobacteria increased. The results of the analysis at the genus level showed that the Lactobacillus ( Lactobacillus ) and Clostridium perfringens ( Peptoclostridium ) increased in average, while PseudoPrevotella ( Alloprevotella ) and Porphyromonas ( Porphyromonas) decreased in average proportion. Therefore, the results of species composition analysis at the phylum and genus levels showed that the use of pet probiotics can change the structural composition of canine intestinal flora.

[0014] Therefore, the pet probiotics can increase the number of beneficial bacteria, inhibit the growth of harmful bacteria, and improve the structure of intestinal flora. Preferably, the pet probiotics can reduce the species abundance and diversity of canine intestinal flora. Further preferably, the pet probiotics can increase the proportion of Prevotella, Lactobacillus, and Pseudomonas aeruginosa, and reduce the proportion of Bacteroides.

[0015] The present invention also claims a biological product containing the above-mentioned Pediococcus acidilactici. Preferably, the number of Pediococcus acidilactici in the biological product is ≥ 10×10 9 The biological product can be prepared into a suitable dosage form for use in the above-mentioned probiotic application, preferably a lyophilized powder or soft capsule containing the Pediococcus acidilactici.

[0016] The present invention isolates and screens a lactic acid Pediococcus strain that can improve the intestinal flora of dogs from the intestines of healthy dogs. Its colony morphology and molecular biological identification show that it is a new lactic acid Pediococcus strain. Through whole genome sequencing, its genome sequence is analyzed and compared with the comprehensive database of virulence factors of pathogenic bacteria (VFDB) and the comprehensive antibiotic resistance database (CARD) by BLAST. No virulence factor-related genes and antibiotic resistance genes were found. The analysis experiment of the intestinal flora of dogs shows that it can increase the number of beneficial bacteria, inhibit the growth of harmful bacteria, and improve the structure of intestinal flora. Specifically, the pet probiotics can increase the proportion of Prevotella, Lactobacillus, and Pseudomonas aeruginosa, and reduce the proportion of Bacteroides.

[0017] Collection information:

[0018] Bacteria name: Pediococcus acidilactici

[0019] Latin: Pediococcus acidilactici

[0020] Strain number: DC-S001.

[0021] Classification name: Pediococcus acidilactici Pediococcus acidilactici.

[0022] Depository: China General Microbiology Culture Collection Administration Committee General Microbiology Center.

[0023] The abbreviation of the collection agency is: CGMCC.

[0024] Address of the preservation institution: No. 3, Yard 1, Beichen West Road, Chaoyang District, Beijing.

[0025] Deposit number: CGMCC No.27239.

[0026] Date of preservation: April 27, 2023. BRIEF DESCRIPTION OF THE DRAWINGS

[0027] Figure 1 The microscopic examination results of Pediococcus acidilactici of the present invention.

[0028] Figure 2 Venn diagram analysis of Alpha diversity of intestinal flora in dogs in different experimental groups.

[0029] Figure 3 Rank-Abundance curves of intestinal flora in dogs in different experimental groups.

[0030] Figure 4 Principal coordinate analysis of intestinal flora in dogs in different experimental groups.

[0031] Figure 5 Column charts of the intestinal flora of dogs in different experimental groups at the phylum level and genus level.

[0032] Figure 6 Heatmap analysis of intestinal flora in dogs in different experimental groups.

[0033] Figure 7 Analysis of the significance of species differences in canine intestinal flora among different experimental groups.

[0034] in Figure 1-Figure 7 The diagrams are as follows: Con: initial control group; Con1: final control group; BLD: competitor Saccharomyces boulardii group before intervention; BLD1: competitor Saccharomyces boulardii group after intervention; Probiotic: experimental group; Probiotic1: experimental group after intervention. DETAILED DESCRIPTION

[0035] The present invention is further described below through specific examples, but the examples do not limit the scope of patent protection of the present invention in any way. Equivalent substitutions made by those skilled in the art based on the present invention are all included in the scope of patent protection of the present invention.

[0036] Example 1: Isolation and culture, homology analysis and strain identification of Pediococcus acidilactici DC-S001 of the present invention

[0037] The small intestine of a healthy dog ​​was washed with sterile PBS buffer. The collected small intestinal lavage fluid samples were diluted 10 times in a gradient and evenly spread on the MRS selective medium plate, and cultured anaerobically at 37℃ for 24-48 hours. Then a single clone was picked and inoculated into the MRS broth medium, and then the single clone colony was continuously picked for streaking until a pure single colony was obtained. The screened lactic acid bacteria strain was mixed with the bacterial solution with glycerol and frozen at -80℃ for later use.

[0038] Screen out the milky white colonies that are the size of a white needle tip and have smooth edges. Perform Gram staining on the isolated and purified bacteria according to the method in the Bergey's Manual of Bacterial Identification. Observe the bacterial morphology under a microscope. The morphology is as follows: Figure 1 Microscopic examination confirmed that the strain was milky white and a Gram-positive strain.

[0039] The isolated strain was selected and a pair of universal primers 27f / 1492r were used for 16S rRNA colony PCR amplification. The amplified product was run on 10 g / L agarose gel electrophoresis. The PCR product was recovered with a Gel Extraction Kit and sent to a gene sequencing company for sequencing and identification. 16S rRNA sequencing identified that it was different from the existing lactic acid Pediococcus and was a new strain. Pediococcus acidilactici The homology is 88.76%.

[0040] The strain identification of Pediococcus acidilactici DC-S001 of the present invention was carried out according to the Bergey's Species Identification Manual and the strain identification method of Pediococcus acidilactici in the existing literature. The identification results of its physiological and biochemical characteristics are shown in Table 1.

[0041] Table 1 Identification of physiological and biochemical characteristics of Pediococcus acidilactici DC-S001 of the present invention

[0042] project result project result glucose + Salicin - Galactose + Oxidase test - Cellobiose + 1%Sodium hippurate 1% - maltose + Hydrogen sulfide test - sucrose - Starch hydrolysis test - Rhamnose - Indole test - fructose + Nitrate gas production test - Raffinose - Nitrate reduction test - lactose - Methyl red test + L-Rhamnose - VP test - Arabinose + Hydrogen peroxide test - Xylose + Mannitol -

[0043] +: positive reaction; -: negative reaction.

[0044] Example 2: Effect of the probiotics of the present invention on the improvement of canine intestinal flora structure

[0045] Experimental conditions: This experiment was conducted at the experimental base of the Shanghai Veterinary Research Institute of the Chinese Academy of Agricultural Sciences. The experimental dogs were Labrador retrievers, with a total of 15 dogs.

[0046] Feeding and management method: The dogs were randomly divided into a control group of five, a competitor group of five, and an experimental group of five. The dogs were fed with a complete feed, wherein the protein content of the complete feed was 28-34%, and one meal was fed daily. The competitor group used Saccharomyces boulardii probiotics, and the experimental group used the lyophilized powder of the pet probiotics of the present invention, 1g per day, for one month. Adequate drinking water and ventilation of the kennels were ensured, and regular immunization and deworming were carried out. The competitor group used Saccharomyces boulardii probiotics produced by Qingdao Wangpai Animal Health Products Co., Ltd. (guaranteed value of product ingredient analysis: brewer's yeast ≥1.0×10 9 CFU / g, Bacillus subtilis ≥2.0×10 9 CFU / g, Bacillus licheniformis ≥1.0×10 9 CFU / g, Lactobacillus plantarum ≥4.0×10 8 CFU / g, Streptococcus thermophilus ≥5.0×10 7 CFU / g, moisture ≤8%). The experimental group used the lactic acid Pediococcus DC-S001 of the present invention (product component analysis guarantee value: lactic acid Pediococcus DC-S001 ≥ 10×10 9 CFU / g, moisture ≤10%).

[0047] Sample and data collection, sequencing and bioinformatics analysis:

[0048] 1. Collect anal swab samples

[0049] Anal swab samples were collected aseptically in the early morning at the start and end of the project, followed by high-throughput sequencing and bioinformatics analysis.

[0050] 2. Sample DNA extraction, PCR amplification and high-throughput sequencing

[0051] The total bacterial DNA of all samples was extracted according to the instructions of the EZNA® soil (Omega Bio-tek, Norcross, GA, USA) kit, and the concentration and purity of the extracted DNA were determined using a NanoDrop2000 analyzer. The V3-V4 variable region of the 16S rRNA gene was selected for PCR amplification of the samples, and the primer sequences were as follows: (338F: 5'-ACTCCTACGGGAGGCAGCAG-3' and 806R: 5'-GGACTACHVGGGTWTCTAAT-3'). After amplification, the PCR amplification products were recovered using 2% agarose gel and then purified using AxyPrep DNA Gel Extraction Kit (Axygen Biosciences, Union City, CA, USA). After library construction, sequencing was performed using the Miseq PE300 platform of Illumina (Shanghai Meiji Biomedical Technology Co., Ltd.).

[0052] 3. Bioinformatics Analysis

[0053] All measured data were spliced ​​using fastp software (https: / / github.com / OpenGene / fastp, version 0.20.0), and then spliced ​​using FLASH (http: / / www.cbcb.umd.edu / software / flash, version 1.2.7) software, and then OTU clustering analysis was performed using UPARSE software (http: / / drive5.com / uparse / , version 7.1), and the OTU similarity was set to 97%. Species classification annotation was performed using RDP classifier software (http: / / rdp.cme.msu.edu / , version 2.2), and the Silva16S rRNA database version 138 was selected for comparison, with the threshold set to 70%. Mothur software was used for diversity analysis, and the R language toolkit was used for drawing.

[0054] Experimental data analysis: SPSS24.0 was used for statistical analysis. Quantitative data were expressed as mean±SD. One-way ANOVA was used to compare the means among groups, and Tukey's method was used for pairwise comparison after ANOVA. P<0.05 was considered statistically significant.

[0055] The experimental results are as follows:

[0056] 1. Quality control and operational taxonomic unit (OTU) analysis of intestinal flora sequencing data

[0057] Next generation sequencing of the V3-V4 region of the 16S rRNA coding gene of the intestinal microorganisms of each group of dogs was performed, and then the obtained reads were quality controlled and analyzed. After optimizing the sequencing data, a total of 3,314,318 high-quality sequences and 138,300,3400 bases were obtained, with an average sequencing length of 417 bp (see Table 2).

[0058] Table 2 Sequence information after high-throughput sequencing data optimization

[0059] Number of samples The optimized sequence Number of bases Average sequencing length (bp) 30 3314318 1383003400 417

[0060] The optimized sequences were clustered into OTUs, and bioinformatics statistical analysis was performed on OTUs at a similarity level of 97%. A total of 24 phyla, 55 classes, 135 orders, 243 families, 555 genera, 938 species, and 1879 operational taxonomic units (OTUs) were obtained by annotating bacterial species taxonomy of OTUs.

[0061] 2. Analysis of Alpha Diversity of Canine Intestinal Microbiota

[0062] Alpha diversity analysis was used to compare the species abundance and diversity of canine intestinal flora in different groups.

[0063] Venn diagrams can be used to count the number of common and unique species (such as OTUs) in multiple groups or samples, and can intuitively show the similarity and overlap of species (such as OTUs) in environmental samples. The results showed that the diversity of the intestinal flora of dogs in the control group did not change significantly; the diversity of the intestinal flora of dogs in the experimental group decreased significantly; the diversity of the intestinal flora of dogs in the competitor group also decreased significantly (see Figure 2 ).

[0064] The Rank-Abundance curve is a way to analyze diversity. The vertical axis represents the relative percentage of the number of sequences in the OTU of this level, that is, the number of sequences belonging to this OTU divided by the total number of sequences. The Rank-Abundance curve can be used to explain two aspects of diversity, namely species abundance and species uniformity. In addition, the shape of the curve (degree of smoothness) reflects the uniformity of species in the sample. The flatter the curve, the more uniform the species distribution. In the horizontal direction, the abundance of species is reflected by the width of the curve. The larger the range of the curve on the horizontal axis, the higher the abundance of species. The results showed that the abundance of intestinal flora in the experimental group of dogs was significantly reduced. ( Figure 3 )

[0065] 3. Analysis of Beta Diversity of Canine Intestinal Flora

[0066] The principal coordinates analysis (PCoA) method was used to compare the Beta diversity of the intestinal flora of dogs in different groups. Figure 4 As shown in the figure, the intestinal flora samples of the control group, the competitive product group and the experimental group are distributed in different spatial regions of the coordinate system. PCoA analysis found that the samples were clustered in different regions, indicating that the use of the product changed the microbial classification clusters.

[0067] 4. Analysis of intestinal flora species composition

[0068] According to the results of species taxonomy analysis, the species composition of the intestinal flora of dogs in the control group, competitor group and experimental group was compared at the phylum and genus levels ( Figure 5 ). The results of the analysis at the phylum level showed that the ratio of Firmicutes to Bacteroidota (F / B) in the probiotic intervention group decreased, the average proportion of Fusobacteriota and Campylobacterota decreased, and the average proportion of Proteobacteria increased. The results of the analysis at the genus level showed that the Lactobacillus ( Lactobacillus ) and Clostridium perfringens ( Peptoclostridium ) increased in average, while PseudoPrevotella ( Alloprevotella ) and Porphyromonas ( Porphyromonas ) decreased in average.

[0069] Heatmap uses color gradients to represent the size of data in a two-dimensional matrix or table and presents community species composition information. Clustering is performed based on the similarity of abundance between species or samples. The results show that high-abundance and low-abundance species are clustered in blocks on the community heatmap. The color changes and similarity levels reflect the similarities and differences in community composition of different groups at each classification level. Figure 6 ).

[0070] 5. Analysis of species composition of canine intestinal flora

[0071] The Kruskal-Wallis H test was used to analyze the community abundance data and evaluate the significance of the observed differences.

[0072] The 16S rRNA microbial diversity sequencing technology was used to compare and analyze the structure of the intestinal flora of experimental dogs in different groups, thereby identifying key bacterial species related to pet intestinal health, mainly including Streptococcus ( Streptococcus ), Peptonephila Peptoniphilus ) and Rhodococcus ( Rhodococcus )wait.

[0073] Example 3: Safety experiment of Pediococcus acidilactici DC-S001 for improving canine intestinal flora of the present invention

[0074] The whole genome shotgun (WGS) method was used to construct libraries with different insert fragments, and then the constructed libraries were sequenced separately using the second-generation sequencing technology based on the Illumina MiSeq sequencing platform combined with the third-generation single-molecule sequencing technology based on the PacBio sequencing platform. The second-generation high-throughput sequencing data were assembled using A5-miseq version 20160825 software and SPAdes genome assembler v3.11.1 software to obtain contigs and scaffolds sequences. The third-generation single-molecule sequencing data were assembled using HGAP4 software and CANU (V1.6) software to obtain scaffold sequences. The contigs obtained by splicing the second-generation and third-generation sequencing data were analyzed for colinearity using MUMmer (v3) software to confirm the assembly results of the two, determine the positional relationship between contigs, and fill the gaps between contigs. Finally, the results were corrected again using pilon (version 1.22) software, and the complete sequence was finally spliced. The presence of virulence factor-related genes in the sequenced genome was analyzed by BLAST comparison with 2599 experimentally confirmed virulence factor-related genes collected in the comprehensive database of Virulence Factors of Pathogenic Bacteria (VFDB). The presence of antibiotic resistance genes in the sequenced genome sequence was analyzed by BLAST comparison with antibiotic resistance genes in the Comprehensive Antibiotic Resistance Database (CARD).

[0075] Through BLAST comparison, it was detected that there were no virulence factor-related genes in the whole genome of the Pediococcus acidilactici DC-S001 used for improving the canine intestinal flora of the present invention, and there were no antibiotic resistance genes in the genome sequence, which shows that the Pediococcus acidilactici is highly safe when used for regulating the intestinal flora of pets, and long-term use will not produce antibiotic resistance.

[0076] The present invention analyzes the Alpha diversity of the intestinal flora of dogs in the control group (Con), the competitive product group (BLD) and the experimental group (Probiotic). The results show that the Saccharomyces boulardii probiotics and the pet probiotics of the present invention can reduce the species abundance and diversity of the intestinal flora of dogs. The PCOA method is used to analyze the Beta diversity of the intestinal flora of dogs. The results show that the intestinal flora of the dogs in the control group (Con), the competitive product group (BLD) and the experimental group (Probiotic) have clustered into completely different classification clusters ( Figure 4 ). Therefore, the intestinal flora of the dogs in the control group (Con), the competitive product group (BLD) and the experimental group (Probiotic) have their own characteristics. In order to further analyze the changes in the intestinal flora of the three groups of dogs, the present invention compared and analyzed the changes in the species composition of the intestinal flora of the competitive product group and the control group after probiotic intervention at the phylum classification level and the genus classification level ( Figure 5 ). The results of the analysis at the phylum level showed that the ratio (F / B) of Firmicutes to Bacteroidota in the probiotic intervention group decreased, the average proportion of Fusobacteriota and Campylobacterota decreased, and the average proportion of Proteobacteria increased. The results of the analysis at the genus level showed that the Lactobacillus ( Lactobacillus ) and Clostridium perfringens ( Peptoclostridium ) increased in average, while PseudoPrevotella ( Alloprevotella ) and Porphyromonas ( Porphyromonas ) decreased in average proportion. Therefore, the results of species composition analysis at the phylum and genus levels showed that the use of pet probiotics can change the structural composition of canine intestinal flora.

Claims

1. A pet probiotic that can improve the intestinal flora structure of dogs, the strain is deposited in the China General Microbiological Culture Collection Center, and the collection number is CGMCC No.27239.

2. The pet probiotics capable of improving the intestinal flora structure of dogs according to claim 1, characterized in that: The pet probiotics are Gram-positive bacteria with milky white colonies.

3. The pet probiotics capable of improving the intestinal flora structure of dogs according to claim 1, characterized in that: The pet probiotic genome is free of virulence factor-related genes and antibiotic resistance genes.

4. Use of the pet probiotics according to claim 1 in improving the intestinal flora structure of dogs.

5. The use of pet probiotics according to claim 4, characterized in that: The pet probiotics can increase the number of beneficial bacteria, inhibit the growth of harmful bacteria, and improve the structure of intestinal flora.

6. A biological product comprising the pet probiotics according to claim 1.

7. The biological product according to claim 6, characterized in that The pet probiotics in the biological product are ≥10×10 9 CFU / g.

8. The biological product according to claim 6, characterized in that The biological product is a freeze-dried powder or soft capsule containing the pet probiotics.